
DFS (95% CI)
Overall
n = 109
55.1 (44.1–64.7)
Philadelphia chromosome status
Ph− (n = 83)
54.1 (41.7–65.0)
Ph+ (n = 26)
57.7 (32.4–76.4)
Remission state before blinatumomab initiation in the Ph− subgroup
CR1 (n = 49)
64.8 (48.7–76.9)
CR2+ (n = 29)
30.5 (12.3–51.0)
HSCT before blinatumomab initiation
No HSCT (n = 92)
54.8 (42.6–65.4)
HSCT (n = 17)
56.5 (29.7–76.4)
MRD response within the first two cycles of blinatumomab treatment
MRD response (incl. complete) (n = 70)
61.2 (47.5–72.4)
Persistence or relapse (n = 13)
36.9 (12.5–62.0)
0
20
40
60
80
100